Staphylococcus Aureus Infections - Pipeline Review, H1 2012

Global Markets Direct, May 2012, Pages: 250

Staphylococcus Aureus Infections – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Staphylococcus Aureus Infections - Pipeline Review, H1 2012', provides an overview of the Staphylococcus Aureus Infections therapeutic pipeline. This report provides information on the therapeutic development for Staphylococcus Aureus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections. 'Staphylococcus Aureus Infections - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Staphylococcus Aureus Infections.
- A review of the Staphylococcus Aureus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Staphylococcus Aureus Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Staphylococcus Aureus Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Staphylococcus Aureus Infections pipeline depth and focus of Staphylococcus Aureus Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Staphylococcus Aureus Infections Therapeutic Products under Development, Key Players in Staphylococcus Aureus Infections Therapeutics, Staphylococcus Aureus Infections Pipeline Overview, Staphylococcus Aureus Infections Pipeline, Staphylococcus Aureus Infections Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Staphylococcus Aureus Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Staphylococcus Aureus Infections
Staphylococcus Aureus Infections Therapeutics under Development by Companies
Staphylococcus Aureus Infections Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Staphylococcus Aureus Infections Therapeutics – Products under Development by Companies
Staphylococcus Aureus Infections Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Staphylococcus Aureus Infections Therapeutics Development
Bristol-Myers Squibb Company
United Therapeutics Corporation
GlaxoSmithKline plc
Genentech, Inc.
Takeda Pharmaceutical Company Limited
Ceragenix Pharmaceuticals, Inc.
Piramal Healthcare Limited
Rib-X Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc.
Forest Laboratories, Inc.
Pfizer Inc.
Toyama Chemical Co. Ltd
Wockhardt Limited
Paratek Pharmaceuticals, Inc.
Helix BioMedix, Inc.
Immtech Pharmaceuticals, Inc.
Lorus Therapeutics Inc
Basilea Pharmaceutica Ltd.
Biota Holdings Limited
Oragenics, Inc.
Patrys Limited
SIGA Technologies, Inc.
Theravance, Inc.
CrystalGenomics, Inc.
Phynova Group Ltd
Syntopix Group Plc
PolyMedix, Inc.
e-Therapeutics plc
Achaogen Inc.
Bharat Biotech International Limited
Immupharma Plc
MerLion Pharmaceuticals Pte Ltd
Evolva SA
GlycoVaxyn AG
PLANTON GmbH
MicuRx Pharmaceuticals, Inc.
Destiny Pharma Ltd.
NovaDigm Therapeutics, Inc.
Kenta Biotech Ltd.
aRigen Pharmaceuticals, Inc.
Nabriva Therapeutics AG
Concert Pharmaceuticals, Inc.
Inimex Pharmaceuticals, Inc.
Integrated BioTherapeutics, Inc.
Enanta Pharmaceuticals, Inc.
Canopus BioPharma Incorporated
KYORIN Pharmaceutical Co., Ltd.
Trius Therapeutics, Inc.
Lytix Biopharma AS
Medisyn Technologies, Inc.
PALUMED S.A.
Phico Therapeutics Ltd.
Durata Therapeutics Inc.
PharmaIN Corporation
Excelimmune, Inc.
UNeMed
Staphylococcus Aureus Infections – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Dalbavancin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK1322322 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Plazomicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HB1345 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LOR-220 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aurexis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lysostaphin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-599 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omadacycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LT-29 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK2392105A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK2392103A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK2392019A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WCK 2349 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WCK 4086 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRX-II - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Staphylococcus Aureus Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACH-2881 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CF-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK2392102A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Second Generation Oxas - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EV-035 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KRP-AM1977X - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KRP-AM1977Y - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Quadrivan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Staphylococcus Aureus Infections Therapeutics – Drug Profile Updates
Staphylococcus Aureus Infections Therapeutics – Discontinued Products
Staphylococcus Aureus Infections Therapeutics - Dormant Products
Staphylococcus Aureus Infections – Product Development Milestones
Featured News & Press Releases
May 10, 2012: Kenta Biotech Obtains EU Orphan Drug Status For KBSA301
May 10, 2012: Kenta Biotech Obtains EU Orphan Drug Status For KBSA301
May 10, 2012: Kenta Biotech Obtains EU Orphan Drug Status For KBSA301
May 07, 2012: NovaDigm Therapeutics Presents Positive Safety And Immunogenicity Data In Second Phase I Study For NDV-3 Vaccine
May 07, 2012: NovaDigm Therapeutics Presents Positive Safety And Immunogenicity Data In Second Phase I Study For NDV-3 Vaccine
May 02, 2012: NovaBay Announces Publication Of Key Data On Aganocide Compound
Apr 30, 2012: CrystalGenomics Initiates Phase II CG400549 Study For Complicated Acute Bacterial Skin And Skin Structure Infections
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I
Apr 20, 2012: PolyMedix To Review Full Results From Phase II Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic
Apr 02, 2012: PolyMedix's PMX-30063 Defensin-Mimetic Antibiotic Demonstrates Activity Against Drug-Resistant Bacterial Pathogens
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Staphylococcus Aureus Infections, H1 2012
Products under Development for Staphylococcus Aureus Infections – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Development by Companies, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012
Bristol-Myers Squibb Company, H1 2012
United Therapeutics Corporation, H1 2012
GlaxoSmithKline plc, H1 2012
Genentech, Inc., H1 2012
Takeda Pharmaceutical Company Limited, H1 2012
Ceragenix Pharmaceuticals, Inc., H1 2012
Piramal Healthcare Limited, H1 2012
Rib-X Pharmaceuticals, Inc., H1 2012
Achillion Pharmaceuticals, Inc., H1 2012
BioMarin Pharmaceutical Inc., H1 2012
Forest Laboratories, Inc., H1 2012
Pfizer Inc., H1 2012
Toyama Chemical Co. Ltd, H1 2012
Wockhardt Limited, H1 2012
Paratek Pharmaceuticals, Inc., H1 2012
Helix BioMedix, Inc., H1 2012
Immtech Pharmaceuticals, Inc., H1 2012
Lorus Therapeutics Inc, H1 2012
Basilea Pharmaceutica Ltd., H1 2012
Biota Holdings Limited, H1 2012
Oragenics, Inc., H1 2012
Patrys Limited, H1 2012
SIGA Technologies, Inc., H1 2012
Theravance, Inc., H1 2012
CrystalGenomics, Inc., H1 2012
Phynova Group Ltd, H1 2012
Syntopix Group Plc, H1 2012
PolyMedix, Inc., H1 2012
e-Therapeutics plc, H1 2012
Achaogen Inc., H1 2012
Bharat Biotech International Limited, H1 2012
Immupharma Plc, H1 2012
MerLion Pharmaceuticals Pte Ltd, H1 2012
Evolva SA, H1 2012
GlycoVaxyn AG, H1 2012
PLANTON GmbH, H1 2012
MicuRx Pharmaceuticals, Inc., H1 2012
Destiny Pharma Ltd., H1 2012
NovaDigm Therapeutics, Inc., H1 2012
Kenta Biotech Ltd., H1 2012
aRigen Pharmaceuticals, Inc., H1 2012
Nabriva Therapeutics AG, H1 2012
Concert Pharmaceuticals, Inc., H1 2012
Inimex Pharmaceuticals, Inc., H1 2012
Integrated BioTherapeutics, Inc., H1 2012
Enanta Pharmaceuticals, Inc., H1 2012
Canopus BioPharma Incorporated, H1 2012
KYORIN Pharmaceutical Co., Ltd., H1 2012
Trius Therapeutics, Inc., H1 2012
Lytix Biopharma AS, H1 2012
Medisyn Technologies, Inc., H1 2012
PALUMED S.A., H1 2012
Phico Therapeutics Ltd., H1 2012
Durata Therapeutics Inc., H1 2012
PharmaIN Corporation, H1 2012
Excelimmune, Inc., H1 2012
UNeMed, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Staphylococcus Aureus Infections Therapeutics – Drug Profile Updates
Staphylococcus Aureus Infections Therapeutics – Discontinued Products
Staphylococcus Aureus Infections Therapeutics – Dormant Products
Staphylococcus Aureus Infections Therapeutics – Dormant Products (Contd..1)
Staphylococcus Aureus Infections Therapeutics – Dormant Products (Contd..2)

List of Figures
Number of Products under Development for Staphylococcus Aureus Infections, H1 2012
Products under Development for Staphylococcus Aureus Infections – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013
• Herpes Simplex Infections - Pipeline Review, H1 2013
• Rotavirus Infections – Pipeline Review, H1 2013
• Candidiasis - Pipeline Review, H1 2013
• Lung Infections – Pipeline Review, H1 2013
• Community-Acquired Infections – Pipeline Review, H1 2013
• Burns - Pipeline Review, H1 2013
• Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics
• Ebola Viral Infections – Pipeline Review, H1 2013
• Inflammatory Bowel Disease - Pipeline Review, H1 2013